Cargando…
Knowledge of HbA1c and LDL‐C treatment goals, subjective level of disease‐related information and information needs in patients with atherosclerotic cardiovascular disease
BACKGROUND/HYPOTHESIS: Risk factor control of diabetes mellitus (DM) and especially dyslipidemia remains unsatisfactory in patients with atherosclerotic cardiovascular disease (ASCVD). We aimed to analyze the knowledge of low‐density lipoprotein cholesterol (LDL‐C) and glycated hemoglobin (HbA1c) tr...
Autores principales: | Brockmeyer, Maximilian, Wies, Emilia, Joerges, Jamuna, Sommer, Jana, Borgmann, Sandra Olivia, Chernyak, Nadja, Lin, Yingfeng, Parco, Claudio, Schulze, Volker, Heinen, Yvonne, Kelm, Malte, Icks, Andrea, Perings, Stefan, Wolff, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933116/ https://www.ncbi.nlm.nih.gov/pubmed/36448416 http://dx.doi.org/10.1002/clc.23948 |
Ejemplares similares
-
Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis
por: Lin, Yingfeng, et al.
Publicado: (2022) -
Supplementary use of HbA1c as hyperglycemic criterion to detect metabolic syndrome
por: Siu, Parco M, et al.
Publicado: (2014) -
The relationship between HbA(1c) and ultrasound plaque textures in atherosclerotic patients
por: Huang, Xiao-Wei, et al.
Publicado: (2016) -
Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017) -
HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)